Kumagai, Shogo
Togashi, Yosuke http://orcid.org/0000-0001-9910-0164
Kamada, Takahiro
Sugiyama, Eri
Nishinakamura, Hitomi
Takeuchi, Yoshiko
Vitaly, Kochin
Itahashi, Kota
Maeda, Yuka
Matsui, Shigeyuki
Shibahara, Takuma http://orcid.org/0000-0003-1559-9805
Yamashita, Yasuho
Irie, Takuma
Tsuge, Ayaka
Fukuoka, Shota
Kawazoe, Akihito
Udagawa, Hibiki
Kirita, Keisuke
Aokage, Keiju
Ishii, Genichiro
Kuwata, Takeshi
Nakama, Kenta
Kawazu, Masahito
Ueno, Toshihide http://orcid.org/0000-0002-7408-7298
Yamazaki, Naoya
Goto, Koichi http://orcid.org/0000-0002-3023-2510
Tsuboi, Masahiro
Mano, Hiroyuki http://orcid.org/0000-0003-4645-0181
Doi, Toshihiko
Shitara, Kohei
Nishikawa, Hiroyoshi http://orcid.org/0000-0001-6563-9807
Article History
Received: 26 January 2019
Accepted: 28 July 2020
First Online: 31 August 2020
Competing interests
: Y. Togashi has received honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical, MSD and Boehringer Ingelheim and has received research funding from AstraZeneca and KOTAI Biotechnologies outside the scope of this work. T.S. and Y.Y. are employees of Hitachi, Ltd. (Hitachi provided support in the form of salaries for authors T.S. and Y.Y. but did not have any additional role in the study). T. Kuwata has received research funding from Ono Pharmaceutical and has received honoraria from Chugai Pharmaceutical outside this work. K.G. has received honoraria and research funding from Bristol-Myers Squibb, Chugai Pharmaceutical and Ono Pharmaceutical and has received research funding from AstraZeneca, MSD, Merck Serono and F. Hoffmann–La Roche outside the scope of this work. H.M. has served as a member of the scientific advisory board for Chugai Pharmaceutical and has received research funding from Ono Pharmaceutical outside the scope of this work. T.D. has received research funding from Merck Serono, MSD, Chugai Pharmaceutical and Bristol-Myers Squibb outside the scope of this work. K.S. has served as a member of the scientific advisory board for Ono Pharmaceutical, Eli Lilly, Bristol-Myers Squibb, Astellas Pharma, Takeda and Pfizer; has received research funding from Ono Pharmaceutical, Eli Lilly, Sumitomo Dainippon Pharma, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical and MSD; and has received honoraria from Novartis, AbbVie and Yakult outside the scope of this work. H. Nishikawa received research funding from Ono Pharmaceutical and BD Japan for this work and has received honoraria and research funding from Chugai Pharmaceutical, MSD and Bristol-Myers Squibb; honoraria from Ono Pharmaceutical; and research funding from Taiho Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, Zenyaku Kogyo, Oncolys BioPharma, Debiopharm, Asahi-Kasei, SRL, Fujifilm, Astellas Pharma, Sumitomo Dainippon Pharma and Sysmex outside the scope of this study. H. Nishikawa is the primary inventor on pending patents PCT/JP2019/02163 belonging to the National Cancer Center Japan and Ono Pharmaceutical and PCT/JP2020/0059919 belonging to the National Cancer Center Japan and BD Biosciences. T.S. has a pending US patent 16/117260 belonging to Hitachi, Ltd. All other authors declare no competing interests.